admin – Page 7981 – Get News Story

Anticipated Surge in Neurofibromatosis Market Growth, Assessed by DelveInsight | Companies – Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics

“Neurofibromatosis Market”

(Albany, USA) DelveInsight’s “Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast

Some of the key facts of the Neurofibromatosis Market Report:

The Neurofibromatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
As per Le et al. (2022), neurofibromatosis type 1 makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. Neurofibromatosis type 2 makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410
Around 16,874 diagnosed cases of NF-2 were found to be prevalent worldwide in 2022, with 10,508 cases found in the US alone. This number of cases is anticipated to increase between 2019 and 2032
In a research by Ejerskov et al. (2021), five patients (30%) with a mosaic form of neurofibromatosis type 1 (NF1) exhibited plexiform neurofibromas out of a total of 17 patients. In their investigation, which included nine papers as well, the researchers came to the conclusion that out of 126 individuals with MNF1, 19 (15%) of them had a plexiform neurofibroma
For paediatric patients with neurofibromatosis type 1 (NF1), a rare and disfiguring illness, aged 2 years or older, Selumetinib became the first medication to receive FDA approval in 2020.
A large number of pharmaceutical companies are entering this illness area as a result of scientific advancements. NFX-179 Gel, Mirdametinib, and FCN-159 are a few new medications
Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
The Neurofibromatosis epidemiology based on type-specific cases analyzed that the prevalent cases of Neurofibromatosis is highest for NF1
The Neurofibromatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis pipeline products will significantly revolutionize the Neurofibromatosis market dynamics.

Neurofibromatosis Overview

A collection of hereditary diseases known as neurofibromatosis (NF) largely damage the body’s nerve cells’ ability to grow and develop. The three primary varieties of neurofibromatosis are schwannomatosis, neurofibromatosis type 1 (NF1), and type 2 (NF2). These diseases have unique clinical characteristics and are brought on by mutations in various genes.

Get a Free sample for the Neurofibromatosis Market Report – https://www.delveinsight.com/report-store/neurofibromatosis-market

Neurofibromatosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurofibromatosis Epidemiology Segmentation:

The Neurofibromatosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Neurofibromatosis
Prevalent Cases of Neurofibromatosis by severity
Gender-specific Prevalence of Neurofibromatosis
Diagnosed Cases of Episodic and Chronic Neurofibromatosis

Download the report to understand which factors are driving Neurofibromatosis epidemiology trends @ Neurofibromatosis Epidemiology Forecast

Neurofibromatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis market or expected to get launched during the study period. The analysis covers Neurofibromatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neurofibromatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurofibromatosis Therapies and Key Companies

FCN-159: Fosun Pharmaceutical
Mirdametinib: SpringWorks Therapeutics
NFX-179 Gel: NFlection Therapeutics, Inc.
HL-085: Shanghai Kechow Pharma
RAD001: Everolimus: Novartis
NFX-179 gel: NFlection Therapeutics, Inc.
Selumetinib: Merck Sharp & Dohme LLC
FCN-159: Shanghai Fosun Pharma
Trametinib: Novartis
Binimetinib: Array BioPharma
REC-2282: Recursion Pharma
AZD2014: Astrazeneca
Lapatinib: GlaxoSmithKline
Icotinib: Betta Pharma
Bevacizumab: Genentech, Inc.

Discover more about therapies set to grab major Neurofibromatosis market share @ Neurofibromatosis Treatment Market

Scope of the Neurofibromatosis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neurofibromatosis Companies: Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., Shanghai Kechow Pharma, Novartis, NFlection Therapeutics, Inc., Merck Sharp & Dohme LLC, Shanghai Fosun Pharma, Array BioPharma, Recursion Pharma, Astrazeneca, GlaxoSmithKline, Betta Pharma, Genentech, Inc., and others
Key Neurofibromatosis Therapies: FCN-159, Mirdametinib, NFX-179 Gel, HL-085, RAD001: Everolimus, NFX-179 gel, Selumetinib, FCN-159, Trametinib, Binimetinib, REC-2282, AZD2014, Lapatinib, Icotinib, Bevacizumab, and others
Neurofibromatosis Therapeutic Assessment: Neurofibromatosis current marketed and Neurofibromatosis emerging therapies
Neurofibromatosis Market Dynamics: Neurofibromatosis market drivers and Neurofibromatosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Neurofibromatosis Unmet Needs, KOL’s views, Analyst’s views, Neurofibromatosis Market Access and Reimbursement

To know more about Neurofibromatosis companies working in the treatment market, visit @ Neurofibromatosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Neurofibromatosis Market Report Introduction

2. Executive Summary for Neurofibromatosis

3. SWOT analysis of Neurofibromatosis

4. Neurofibromatosis Patient Share (%) Overview at a Glance

5. Neurofibromatosis Market Overview at a Glance

6. Neurofibromatosis Disease Background and Overview

7. Neurofibromatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurofibromatosis

9. Neurofibromatosis Current Treatment and Medical Practices

10. Neurofibromatosis Unmet Needs

11. Neurofibromatosis Emerging Therapies

12. Neurofibromatosis Market Outlook

13. Country-Wise Neurofibromatosis Market Analysis (2019–2032)

14. Neurofibromatosis Market Access and Reimbursement of Therapies

15. Neurofibromatosis Market Drivers

16. Neurofibromatosis Market Barriers

17. Neurofibromatosis Appendix

18. Neurofibromatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Surge in Neurofibromatosis Market Growth, Assessed by DelveInsight | Companies – Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics

Princeton, NJ, Realtor, Celebrates Start of 12th Year in Business

Lisa Danbrot, a real estate agent in Princeton NJ with Compass is celebrating a significant milestone in her career, beginning her 12th year as a highly respected and valued real estate professional. With a deep commitment to her clients and a wealth of experience, Lisa has become known as a trusted companion and expert guide to all who work with her.

Born and raised in Brooklyn NY, Lisa’s city-to-suburb transition that ultimately led her to Princeton New Jersey was a personal journey that now allows her to connect with clients on a unique level. She believes in the power of synergy, attracting clients who share her appreciation for the qualities that make Princeton a special place to live and call home.

“I leverage my extensive experience to assist my clients in their real estate endeavors effectively. With a background in high-pressure NYC art sales, art publishing project management, and years of practicing and teaching yoga, I bring a unique skill set to real estate. I’m committed to helping my clients navigate the market with focus and proficiency in my role as a real estate agent in Princeton NJ”.

Lisa’s passion for real estate started long ago with the search for her own first home and continued as she obsessively explored properties for herself and others. Inspired by her love of architecture, design, and the concept of home, she realized she could turn her passion into a career and obtained her license in 2012. As her path unfolded, it led to her current work as a real estate agent in Princeton NJ.

For over a decade, Lisa Danbrot has worked in some of the most competitive NJ markets. As a Princeton, NJ, Realtor, she brings all her acumen and savvy to the table. She has cultivated a reputation for her unwavering commitment to her clients, her in-depth knowledge of the local real estate market, and her strategic approach to home purchases and sales.

When asked about her distinctive real estate career, Lisa shares her enthusiasm for the future: “I’ve been in business since December 2012, so I’m celebrating an anniversary this month. I am so grateful for my work and my clients and look forward to many more years of helping people navigate the dynamic world of real estate and reach their goals in the marketplace”.

For those seeking guidance in the Princeton, NJ, real estate market, Lisa Danbrot’s experience and track record is a testament to her dedication and expertise. To learn more about Lisa and her services, visit her website at https://www.compass.com/agents/lisa-danbrot/.

Media Contact
Company Name: Lisa Danbrot Properties | Real Estate Agent in Princeton NJ
Contact Person: Lisa Danbrot
Email: Send Email
Phone: +1 917-674-4109
Address:51 Bainbridge St.
City: Princeton
State: New Jersey 08540
Country: United States
Website: https://www.compass.com/agents/lisa-danbrot/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Princeton, NJ, Realtor, Celebrates Start of 12th Year in Business

Leading Real Estate Agent in Tampa, FL, Confirms: People are Buying Bigger Houses Than Before

In an exciting development for the Tampa real estate market, the leading real estate agent in the region, Aleks Pavlova, has confirmed a notable trend – people are buying bigger houses than ever before. This emerging trend showcases a growing demand for spacious, comfortable, and luxurious homes in the Tampa Bay area.

Tampa has long been a sought-after destination for homebuyers, thanks to its beautiful beaches, vibrant culture, and a thriving job market. However, recent data analyzed by Aleks Pavlova, the leading real estate agent in Tampa, FL, reveals a significant shift in the preferences of prospective homeowners. Homebuyers are increasingly prioritizing spacious living spaces, larger yards, and impressive amenities in their quest for the perfect property.

“Smith&Associates Real Estate has been at the forefront of the Tampa real estate market for years, and our extensive experience and market insight have allowed us to identify this emerging trend,” said Aleks Pavlova, who is recognized as one of the top Realtors in Tampa, FL. “Homebuyers are recognizing the value of larger homes that provide ample space for their families, remote work setups, and recreational activities.”

Key findings from Aleks Pavlova’s analysis include:

Increased Square Footage: The average size of homes purchased in Tampa has seen a substantial increase, with buyers showing a clear preference for larger living spaces.
High Demand for Outdoor Spaces: Homes with spacious yards, gardens, and outdoor amenities like pools and entertainment areas are in high demand, reflecting a growing desire for comfortable outdoor living spaces.
Customization and Luxury Features: Buyers are more inclined to invest in properties with upscale features, such as gourmet kitchens, walk-in closets, home theaters, and smart home technology.
Shift in Home Office Requirements: As remote work becomes a long-term reality for many, dedicated home office spaces or the potential for customization have become key priorities for homebuyers.

Aleks Pavlova and her team of real estate selling agents of Tampa, Florida, have been quick to adapt to this evolving market trend, connecting buyers with the perfect properties that cater to their evolving needs and preferences.

Tampa’s thriving real estate market is poised to meet these demands with a diverse selection of properties, ranging from expansive suburban homes to luxurious waterfront

estates. With low interest rates and an attractive quality of life, Tampa continues to attract homebuyers from all walks of life.

If you’re interested in learning more about the current real estate market trends in Tampa or are considering buying or selling a property in the area, don’t hesitate to contact Aleks Pavlova. With their expertise and dedication to client success, Aleks is ready to assist you in navigating this dynamic and competitive market.

For more information, visit Aleks Pavlova’s website at dreamhomestampabay.com

About the Real Estate Agent:

Aleks Pavlova is a renowned real estate professional with 7 years of experience in the Tampa, FL, market. Her commitment to excellence, in-depth market knowledge, and personalized service have earned them a reputation as a leading real estate agent in the Tampa Bay area.

Media Contact
Company Name: Aleks Pavlova | Real Estate Agent in Tampa FL
Contact Person: Aleks Pavlova
Email: Send Email
Phone: +1 239-333-9588
Address:3801 W Bay to Bay Blvd
City: Tampa
State: Florida 33629
Country: United States
Website: https://dreamhomestampabay.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Tampa, FL, Confirms: People are Buying Bigger Houses Than Before

Top Real Estate Agent in Queens, NY, Celebrates 25 Years in Business

Ahmed Drake, the owner/broker of Innovative Solutions Realty, is celebrating a remarkable milestone in his real estate career as he marks 25 years of dedicated service. With an unwavering commitment to ethical and transparent practices, Ahmed Drake has earned his place as a respected figure in the real estate industry.

Drake’s approach to real estate is a testament to his extensive experience and dedication to his clients as a real estate agent in Queens NY. Unlike many competitors, he provides a comprehensive service that goes beyond the transaction. His holistic approach includes educating clients about the intricacies of the real estate market, guiding them through every step, and ensuring that they make informed, life-enhancing decisions.

“As the owner/broker of Innovative Solutions Realty, I bring over 20 years of combined experience as a Real Estate Agent and Broker licensed in multiple states,” says Ahmed Drake. “My passion lies in not only navigating the real estate market but also in educating and empowering clients, enhancing their understanding of the real estate market and its nuances in the realm of property investment and ownership.”

Innovative Solutions Realty, founded by Ahmed Drake in 2021, is a testament to his dedication and expertise in the real estate industry. With over two decades of experience, Ahmed Drake has consistently provided unparalleled service, marrying the wisdom of years with time-honored expertise and modern, innovative approaches.

“At Innovative Solutions Realty, our mission is to serve our clients with integrity and transparency,” says Ahmed Drake, one of the leading Realtor agents in Queens NY. “We believe in the power of knowledge and strive to ensure that our clients not only achieve their real estate goals but also gain a deeper understanding of the real estate market and the financial implications of their decisions.”

As a respected Queens, NY, Realtor, Ahmed Drake continues to set the standard for excellence in the industry. His dedication to empowering clients through education and his commitment to ethical practices have earned him the trust and respect of buyers and sellers alike.

Ahmed Drake is the owner/broker of Innovative Solutions Realty, a leading real estate agency in Queens, NY. With over 20 years of experience as a real estate agent/broker, Ahmed Drake is committed to providing comprehensive and transparent service to his clients.

Media Contact
Company Name: INNOVATIVE SOLUTIONS REALTY | Real Estate Agent in Queens, NY
Contact Person: Admed Drake
Email: Send Email
Phone: +1 929-335-7700
Address:176-27 137th Ave
City: Queens
State: New York 11434
Country: United States
Website: https://www.innovativesolutionsrealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Queens, NY, Celebrates 25 Years in Business

Anticipated Expansion of Chronic Lower Back Pain Market with Strong Growth Projected during Forecast Period, by DelveInsight | Companies – Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast

“Chronic Lower Back Pain Market”

(Albany, USA) DelveInsight’s “Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast

Some of the key facts of the Chronic Lower Back Pain Market Report:

The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
The Chronic Lower Back Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.

Chronic Lower Back Pain Overview

Acute low back pain can be caused by an injury or other underlying condition, but chronic low back pain (CLBP) lasts for 12 weeks or more. Everyone has had low back pain at some point because it is so prevalent.

Get a Free sample for the Chronic Lower Back Pain Market Report – https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Chronic Lower Back Pain Epidemiology

Chronic Lower Back Pain Epidemiology Segmentation:

The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Lower Back Pain
Prevalent Cases of Chronic Lower Back Pain by severity
Gender-specific Prevalence of Chronic Lower Back Pain
Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies

LY3016859: Eli Lilly and Company
Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
Semdexa (SP-102): Scilex Holding
Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
AMG0103: AnGes MG, Inc
Duloxetine: Eli Lilly and Company
buprenorphine: Braeburn Pharmaceuticals
Celebrex 200mg: Pfizer
Oxymorphone ER: Endo Pharmaceuticals
PP353: Persica Pharmaceuticals
Oxycodone DETERx: Collegium Pharma
Bicifadine: DOV Pharma
OROS hydromorphone: Mallinckrodt
EN3324 (axomadol): Grünenthal GmbH
ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market

Scope of the Chronic Lower Back Pain Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Lower Back Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Lower Back Pain Market Access and Reimbursement

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Lower Back Pain Market Report Introduction

2. Executive Summary for Chronic Lower Back Pain

3. SWOT analysis of Chronic Lower Back Pain

4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance

5. Chronic Lower Back Pain Market Overview at a Glance

6. Chronic Lower Back Pain Disease Background and Overview

7. Chronic Lower Back Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Lower Back Pain

9. Chronic Lower Back Pain Current Treatment and Medical Practices

10. Chronic Lower Back Pain Unmet Needs

11. Chronic Lower Back Pain Emerging Therapies

12. Chronic Lower Back Pain Market Outlook

13. Country-Wise Chronic Lower Back Pain Market Analysis (2019–2032)

14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies

15. Chronic Lower Back Pain Market Drivers

16. Chronic Lower Back Pain Market Barriers

17. Chronic Lower Back Pain Appendix

18. Chronic Lower Back Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anticipated Expansion of Chronic Lower Back Pain Market with Strong Growth Projected during Forecast Period, by DelveInsight | Companies – Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast

Leading Real Estate Agent in Beaufort, SC, Celebrates 8th Year In Business

Chuck Newton was looking for a new home and a chance to start another successful business. After selling real estate in ten states and two countries, Newton had the ability and understanding of the real estate industry to find success.

This was eight years ago as a buyer’s agent. Today, Newton is a successful real estate agent in Beaufort, South Carolina. Recognized by many as the leading Realtor in the area for many years, Newton notes his success did not come easily. It has taken hard work and dedication to the craft.

“My history of real estate success is part of the reason why so many people choose me as their real estate listing agent Beaufort, SC. I have followed the market and its changes carefully. This means I help the buyers and sellers find the best of the best. In the end, both are happy,” said Newton.

Outside of his knowledge, Newton works hard for his clients and customers, providing unmatched attention and customer service. This means being honest and forthright, helping clients make the concessions they often have to make when it comes to a home.

“I do everything I can for my clients and do it with a professional approach and professional experience that is unmatched with many real estate agents Beaufort, SC,” continued Newton.

Chuck Newton and the Bay Street Realty Group of Beaufort South Carolina have a highly dynamic and active website with properties coming onto and off of the market regularly. Go to https://cnewton.baystreetrealtygroup.com/ for details.

Media Contact
Company Name: Chuck Newton – Bay Street Realty Group | Real Estate Agent in Beaufort SC
Contact Person: Chuck Newton
Email: Send Email
Phone: +1 843-838-1888
Address:701 Bay Street
City: Beaufort
State: South Carolina 29902
Country: United States
Website: https://cnewton.baystreetrealtygroup.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Beaufort, SC, Celebrates 8th Year In Business

Leading Real Estate Agent in San Antonio, Texas, Celebrates 7 Years In Business

David Beere has done something only about 10 percent of small businesses do. He and his real estate agency have made it past five years. A business that survives after five years has an excellent chance of full survival.

David Beere is a real estate listing agent in San Antonio, TX. He chalks up his success to his approach on client relationships. His goal is to make the client feel like they are heard and valued. He does this through a combination of trust and finding the best possible homes for each and every client, each and every time.

David Beere’s commitment to excellence extends beyond the world of real estate. He is dedicated to fostering a sense of belonging and pride within the neighborhoods he serves. With his extensive experience and unmatched passion for helping people find their dream homes, David Beere remains a trusted name and a leading real estate selling agent of San Antonio, Texas.

“San Antonio is a big, metropolitan city with a diverse community. People coming into the city and its surrounding areas have specific desires and needs in their home choice. I work hard to stay on the pulse of the city and each neighborhood. My goal is to meet as many of the client needs as possible,” said Beere.

Beere has been in the industry since 2017 and does not have any inkling of slowing down or changing his approach to the business and clients.

David Beere’s journey in the real estate industry has been marked by unwavering dedication to his clients and a deep-rooted commitment to excellence. With seven successful years in business, he has not only weathered the challenges but has also thrived in the dynamic San Antonio real estate market.

David Beere is one of the leading Realtors in San Antonio, Texas. His approach to each client means satisfaction each and every time. Learn more at the website. Visit http://www.davidbeere.co/.

Media Contact
Company Name: David Beere, Texas Premier Realty | Real Estate Agent in San Antonio TX
Contact Person: David Beere
Email: Send Email
Phone: +1 210-889-3283
Address:8620 N New Braunfels Ave # 601
City: San Antonio
State: Texas 78217
Country: United States
Website: http://www.davidbeere.co/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in San Antonio, Texas, Celebrates 7 Years In Business

Leading Real Estate Agent in Tulsa, OK, Celebrates 22 Years in Business

Tulsa, Oklahoma is a major metropolitan city with a booming industry sector. This means plenty of people are coming into the city and its many neighborhoods with regularity. They all have one thing in common – they are all looking for a new home.

This means new residents will need the services of a real estate agent in Tulsa, OK. The better choices have a history of success and longevity in the business. There is one agent who is in their third decade of business and is still going strong – the agent that has been recognized as the top Realtor in the area for many years.

Tammy Perry is known as one of the best real estate agents Tulsa, Oklahoma, has to offer. After 22 years, she has helped countless families and individuals find their first or final home. She attributes her success in the industry to the care she has before, during and after each sale as well as one more important element.

“I would guess 80 percent of my business comes from previous clients making recommendations and looking for another home, and that alone says a lot” said Perry.

Perry also has a unique understanding of the Tulsa metro market. This means finding the perfect home for any buyer is something many other Realtors in the area might struggle with.

Tammy Perry is a Realtor agent in Tulsa, Oklahoma, with McGraw Realtors. Their website has a number of available properties entering and leaving the market with regularity. Visit https://www.mcgrawrealtors.com/Bio/tperry for contact information and properties.

Media Contact
Company Name: Tammy Perry – McGraw Realtors | Real Estate Agent in Tulsa OK
Contact Person: Tammy Perry
Email: Send Email
Phone: +1 918-906-8064
Address:10712 S Memorial Dr.
City: Tulsa
State: Oklahoma 74133
Country: United States
Website: https://www.mcgrawrealtors.com/bio/tperry

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Tulsa, OK, Celebrates 22 Years in Business

Orderly Network Introduces Groundbreaking Omnichain SDK: Rapid Perpetual Protocol Development with Built-in Liquidity

Orderly Network’s Omnichain SDK facilitates rapid development of omnichain-enabled PERP DEXs for builders

Orderly Network, an innovative layer that serves both as an omnichain trading infrastructure and an app-chain, offering advanced trading tools and plug-in liquidity – is excited to unleash the Orderly Omnichain SDK, crafted meticulously ‘for devs by devs’. This toolkit is a canvas for developers, enabling them to effortlessly craft powerful protocols and innovative trading instruments. With its intuitive design and enhanced capabilities, the SDK allows developers to focus on creativity and efficiency. This particular SDK is built for the EVM community, as part of Orderly’s omnichain expansion. Previously they SDK was only available on NEAR protocol. Orderly already has several DEX’s as well as CEX’s using their infrastructure to power perps.

Designed for Developers, Tailored for Innovation

The Orderly Omnichain SDK offers a robust and expansive platform tailored for EVM developers, streamlining the creation of perpetual protocols and sophisticated trading tools. This toolkit is akin to a plug-and-play set, offering the flexibility and simplicity of Lego blocks. It empowers developers to construct orderbook-based Perp DEX with precision and ease, significantly reducing development time and effort for web3 teams.

Key features include data fetching, smart contract interaction, account & asset management, orderbook and market data access, and order & position management. Targeted primarily at developers, this SDK simplifies complex tasks, allowing developers to focus on innovation and accelerate product development – serving as an invaluable resource for developers and dApp creators seeking to integrate advanced Orderly functionalities into their applications.

Simplified Integration for EVM Builders

Integration is simplified with a comprehensive suite of webhooks, making the Orderly SDK a one-stop solution for diverse development needs. Orderly Network also provides extensive documentation offering technical details, code samples, and use case examples, alongside a responsive AI chatbot support for immediate query resolution.The Orderly Omnichain SDK is a significant asset for EVM developers, seamlessly merging powerful capabilities with user-friendly design. It revolutionizes the creation of perpetual protocols and advanced trading tools, offering a level of simplicity and flexibility.

This toolkit is set to significantly reduce development time for decentralized trading tools. It’s an essential tool for web3 teams, streamlining development processes and paving the way for innovative, efficient DeFi solutions.

Accessibility and Future Plans

The SDK will be made accessible via Orderly’s GitHub in the coming days and will be announced on all social platforms. Comprehensive tutorials and in-depth documentation are slated also for release.

Orderly’s Omnichain SDK currently supports TypeScript as their initial offering. However, the protocol plans to expand language support to Python and Java, reflecting the diverse needs of the developer community. Its roadmap includes additional documentation, enhanced functionalities, and broader language support, signaling Orderly Network’s commitment to continuous innovation.

Orderly actively encourages developers to join their Discord channel for personalized support and guidance from their experienced developer team. Additionally, they invite developers to participate in their hackathons, offering opportunities for hands-on experience, collaboration, and innovation in a dynamic and supportive environment.

Media Contact
Company Name: Orderly Network
Contact Person: Irene Long
Email: Send Email
Country: United States
Website: www.orderly.network

Stemtech (STEK) Marks 2023 with Sustained Growth and Ongoing Innovation

“As we witness the rapid advancement of our IBPs through the ranks, Stemtech not only celebrates individual successes but also the collective strength of our global team. The exceptional in the last quarter as well as October and November, reflects our commitment to providing a thriving business opportunity,” stated John W. Meyer, President and COO of Stemtech.”

Amidst the bustling field of health and wellness, Stemtech Corporation (STEK) distinguishes itself through innovative solutions and an inspiring story of resilience and growth. Following a strategic restructuring, Stemtech has emerged with a fortified stance, ready to capture exponential growth and broaden its international footprint.

In October, U.S. job openings dropped significantly to their lowest since March 2021, indicating a possible relaxation of the tight labor market. The total number of openings decreased by 617,000 to 8.73 million, a 6.6% fall and below the expected 9.4 million. This decline brought the job openings-to-workers ratio closer to pre-pandemic levels. Despite the drop in openings, hiring remained stable, and quits were unchanged, suggesting continued worker confidence. This data is crucial for the Federal Reserve, which has raised interest rates to manage labor demand and inflation, as they consider future policy decisions. It would be interesting to see if this news could fuel the small cap stocks rally ? With this, we would like to draw your attention to Stemtech Corporation (STEK).

Amidst the bustling field of health and wellness, Stemtech Corporation (STEK) distinguishes itself through innovative solutions and an inspiring story of resilience and growth. Following a strategic restructuring, Stemtech has emerged with a fortified stance, ready to capture exponential growth and broaden its international footprint.

For the uninitiated, Stemtech Corporation, a pioneer in stem cell nutrition wellness, was established on April 18, 2018, succeeding Stemtech International, Inc., which began in 2005. The company achieved recognition on the Inc. 5000 Fastest-Growing Companies list four times between 2010 and 2015. After a significant executive reorganization in 2018, Stemtech continued under new management. It went public in August 2021 as OTCQB: STEK and has since focused on expanding its Independent Business Partners’ opportunities. 2022 saw various initiatives, including new marketing efforts, the launch of the Stemtech AdvanceOffice mobile app, and the introduction of OraStem® Toothpaste and Cellect One™ Rapid Renew Stem Cell Peptide Night Cream. Alejandro Carrillo was promoted to Vice President Global Sales. Stemtech also ranked 11th in momentum among global MLM companies and hosted Field Leadership Business Academies in Aguas Calientes, Mexico and Las Vegas, Nevada.

Navigating Change: A Period of Restructuring

Challenged by the ever-evolving market, Stemtech opted for resilience over retreat. The leadership undertook bold measures to recalibrate operations, drastically reducing costs and streamlining the company’s structure for agility and efficiency.

Preparation for Growth: Operational Efficiency at Its Core

The restructuring was a deliberate, strategic move. Stemtech rigorously evaluated its operations, making crucial adjustments to prime itself for growth. This period of strategic refinement resulted in a robust, focused organization ready to take on the world.

Reopening the Doors to Success: Colombia and Ecuador Expansion

Stemtech’s growth narrative includes a significant leap into opening Colombia and an expanded product offering in Ecuador, markets ripe with potential and symbolic of the company’s commitment to global wellness. This expansion underscores Stemtech’s intent to deliver its revolutionary products to a broader demographic.

Strengthening Core Markets

Even as it expands, Stemtech solidifies its presence in established markets, upholding its pledge to quality and innovation. Its products, steeped in advanced science, continue to earn trust and loyalty, enhancing the company’s strong market position.

Celebrating New Milestones and Acknowledging Achievements

Stemtech (OTCQB:STEK), a trailblazer in natural, plant-based stem cell nutrition, celebrates remarkable NEW Rank Advancements among its Independent Business Partners (IBPs) in 2023. These prestigious recognitions include Diamond, Crown Diamond, and Presidents Club achievements. Stemtech honors the dedication and excellence of its IBPs, whose hard work fuels the company’s success. The company’s “stemceutical™” technology, a patented marvel, empowers the mobilization of stem cells, reflecting Stemtech’s dedication to scientific innovation. The success of its IBPs, particularly Maria Felix Rodriguez, Olga Lidia de Leon Perez, and Ana Nunez, who have recently achieved prestigious ranks, underscores the potency of Stemtech’s business model.

A Promising Future

John W. Meyer, President and COO, extols the IBPs’ progress, indicative of Stemtech’s robust business opportunity. The company anticipates re-entering the Colombian market and expanding in Ecuador, with CEO Charles S. Arnold guiding towards cash flow positivity and sustained growth following the strategic overhaul. Stemtech’s journey is a testament to resilience, adaptability, and a vision for a healthier world. With strategic market reentries, an emphasis on core competencies, and a celebration of its community’s success, Stemtech stands on the verge of an unprecedented era of growth. Stemtech’s story is about a company and a community united in transforming lives across the globe. Currently, STEK is trading at $0.0221, and if things proceed as planned for the company, there appears to be considerable upside potential, especially considering its 52-week high of $0.3695.

For more information on STEK, please watch the video below:

Video Link: https://www.youtube.com/embed/_Usj0SUwrNM

Some of the most active penny stocks to place on top of radar include Bitfarms Ltd. (BITF) traded at $2, up 14.29% with a volume of 33.29M and a market cap of $650.07M; TeraWulf Inc. (WULF) at $1.605, gaining 4.22% with 11.95M shares traded and a market cap of $386.67M; SunHydrogen, Inc. (HYSR) priced at $0.0146, up 11.45% with a volume of 8.32M and a market cap of $73.89M; Sphere 3D Corp. (ANY) at $1.42, increasing by 32.71% with 9.43M shares traded and a market cap of $20.38M; and Bit Brother Limited (BETS) at $0.0881, up 26.95% with a high volume of 258.36M and a market cap of $18.61M (Data from Tuesday Dec 5th, 12:30 pm EST)

Source:

https://finance.yahoo.com/news/stemtech-continues-demonstrate-remarkable-growth-133000836.html

https://finance.yahoo.com/quote/STEK/

Disclaimer: FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated five hundred dollars by a 3rd party Bullzeyemedia LLC for advertisement and content distribution services on STEK for 12/05/2023. We own zero shares of STEK. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stemtech (STEK) Marks 2023 with Sustained Growth and Ongoing Innovation